<!DOCTYPE html>
<html lang="en">
<head>
<?php $id='1923-1253'; include '../../seo.php';?>
<?php include '../../side-nav.php';?>
<div class="page-content">
<!--section-->
<div class="section mt-0">
<div class="breadcrumbs-wrap">
<div class="container">
<div class="breadcrumbs">
<a href="https://sprintdiagnostics.in/">Home</a>
<a href="https://www.sprintdiagnostics.in/hyderabad/test/">Test</a>
<span>Myeloma Cytogenetics-2: FISH Analysis for del17p, IGH Breakapart, del13q, t(4;14), and t(14;16) </span>
</div>
</div>
</div>
</div>
<!--//section-->
<!--section-->
<div class="section page-content-first">
<div class="container mt-6">
<div class="row">
<div class="col-md-8 col-lg-8 mt-0 mt-md-0 mb-4">
<h1 class="test-h1">Myeloma Cytogenetics-2: FISH Analysis for del17p, IGH Breakapart, del13q, t(4;14), and t(14;16) </h1>
<div class="post-text">
<p>Myeloma Cytogenetics-2 is a specialized diagnostic test that employs Fluorescence In Situ Hybridization (FISH) to detect genetic abnormalities, such as del17p, IGH breakapart, del13q, t(4;14), and t(14;16), associated with multiple myeloma. Multiple myeloma is a cancer of plasma cells, which are a type of white blood cell responsible for producing antibodies. This test helps in understanding the genetic makeup of myeloma cells, which is critical for diagnosis, risk assessment, and guiding treatment strategies. </p>
<p>Multiple myeloma is a malignancy characterized by the abnormal proliferation of plasma cells within the bone marrow. These abnormal cells produce a large amount of a single type of antibody, which can cause various problems in the body. In multiple myeloma, genetic abnormalities are common, and they can play a significant role in the behavior of the disease. Myeloma Cytogenetics-2 uses FISH analysis, a highly sensitive technique that uses fluorescent probes to detect specific DNA sequences on chromosomes. This test focuses on identifying key genetic abnormalities, such as del17p, IGH breakapart, del13q, t(4;14), and t(14;16), which have been associated with the progression and prognosis of multiple myeloma. </p>
<div class="table-wrap">
<table class="table table-striped">
	<thead>
		<tr>
			<th scope="col">Test Name</th>
			<td scope="col">Myeloma Cytogenetics-2: FISH Analysis for del17p, IGH Breakapart, del13q, t(4;14), and t(14;16) </td>
		</tr>
	</thead>
	<tbody>
		<tr>
			<th scope="row">Sample Type</th>
			<td>Bone Marrow </td>
		</tr>
		<tr>
			<th scope="row">Preparations Required</th>
			<td>5 Days </td>
		</tr>
		<tr>
			<th scope="row">Report Time</th>
			<td>No special preparation is required for this test. </td>
		</tr>
		<tr>
			<th scope="row">Price in Hyderabad</th>
			<td>â‚¹ 13000 </td>
		</tr>
	</tbody>
</table>
</div>
<div class="post-text">
	<h2 class="test-h2 mt-3">What is Fluorescence In Situ Hybridization (FISH) and why is it used in this test? </h2>
	<p>FISH is a molecular cytogenetic technique that uses fluorescent probes to bind to specific DNA sequences on chromosomes. It is a highly sensitive and specific method that allows for the detection of genetic abnormalities such as deletions, translocations, and amplifications, which are common in multiple myeloma. </p>
	<h2 class="test-h2 mt-3"> What is the significance of del17p in multiple myeloma? </h2>
	<p>Del17p refers to a deletion of part of chromosome 17. This particular deletion is associated with an aggressive form of multiple myeloma and is often linked to resistance to standard therapies. </p>
	<!--section achieved-->
	<?php include "../../include/iconsbox.php" ?>
	<!--//section achieved-->
	<h2 class="test-h2 mt-3">What does IGH breakapart mean? </h2>
	<p>IGH breakapart refers to rearrangements involving the immunoglobulin heavy chain gene, which is located on chromosome 14. These rearrangements are common in multiple myeloma and can be associated with a more aggressive disease course. </p>
	<h2 class="test-h2 mt-3">What is the importance of detecting del13q? </h2>
	<p>Del13q is a deletion of a part of chromosome 13. It is one of the most common cytogenetic abnormalities in multiple myeloma and is associated with a variable prognosis. </p>
	<h2 class="test-h2 mt-3">Why are t(4;14) and t(14;16) translocations important? </h2>
	<p>These are specific chromosomal translocations involving exchanges of genetic material between chromosomes 4 and 14 or 14 and 16. They are associated with a poorer prognosis and may influence the choice of treatment. </p>
	<h2 class="test-h2 mt-3">How is the bone marrow sample collected for this test? </h2>
	<p>The sample is collected through a bone marrow aspiration procedure, where a needle is inserted into the bone, typically the hip bone, to extract a small amount of bone marrow. </p>
	<h2 class="test-h2 mt-3">How will the results of this test influence my treatment? </h2>
	<p>Identifying specific genetic abnormalities helps your doctor understand the aggressiveness of the disease and predict how it may respond to different treatments. This can be used to tailor a treatment plan to your specific condition. </p>
	<h2 class="test-h2 mt-3">What are the treatment options for multiple myeloma with these genetic abnormalities? </h2>
	<p>Treatment options include chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, and supportive care. The presence of certain genetic abnormalities may indicate the need for more aggressive or targeted treatment approaches. </p>
	<h2 class="test-h2 mt-3">Can multiple myeloma be cured? </h2>
	<p>Currently, there is no cure for multiple myeloma, but it is treatable. Advances in treatment have significantly improved survival and quality of life for patients with this disease. </p>
	<h2 class="test-h2 mt-3"> What are the risks associated with the bone marrow aspiration procedure? </h2>
	<p>There is a small risk of infection, bleeding, and bruising at the needle site. The healthcare team takes precautions to minimize these risks. </p>
	<h2 class="test-h2 mt-3">How often should this test be done? </h2>
	<p>This test is generally performed at diagnosis to assess the genetic characteristics of the disease. It may be repeated if there is a change in your condition or to monitor the response to treatment. </p>
	<h2 class="test-h2 mt-3"> Is there any lifestyle modification that can affect the progression of multiple myeloma? </h2>
	<p>While lifestyle changes cannot cure multiple myeloma, maintaining a healthy lifestyle with a balanced diet and regular exercise can improve overall health and may positively influence response to treatment. </p>
	<h2 class="test-h2 mt-3">Which doctor should I consult if the results are abnormal? </h2>
	<p>You should consult a hematologist or oncologist who specializes in blood cancers for a detailed evaluation and discussion of treatment options. </p>
	<h2 class="test-h2 mt-3">What is the prognosis for multiple myeloma with these genetic abnormalities? </h2>
	<p>The prognosis varies depending on the genetic abnormalities present. For example, patients with del17p or t(4;14) tend to have a poorer prognosis compared to those without these abnormalities. </p>
	<h2 class="test-h2 mt-3">Can the results of this test change over time? </h2>
	<p>Yes, the genetic characteristics of multiple myeloma can evolve over time, especially under the pressure of treatment. This is why repeated testing may sometimes be necessary. <br><br>
Understanding the genetic characteristics of multiple myeloma is crucial for effective management and treatment of the disease. Myeloma Cytogenetics-2 (FISH analysis for del17p, IGH breakapart, del13q, t(4;14), and t(14;16)) provides valuable insights into the genetic makeup of myeloma cells, aiding in risk stratification and personalized treatment planning. Keep an open communication channel with your doctor regarding the results and implications for your specific situation.
 </p>
	
</div>		
</div>			
</div>
<!--form section-->
<?php include "../../include/bookslot.php" ?>
<!--form section-->
</div>
</div>
<!--//section-->
</div>
</div>
<?php include '../../footer.php';?>
</body>
</html>